Meeting
2018 ASCO Annual Meeting
Exhausted CD8+ cells (Tex) to predict response to PD-1 therapy in estrogen receptor (+) hormone therapy resistant breast cancer predictive of response to immune checkpoint inhibitors after epigenetic priming.
Authors
Pamela N. Munster
University of California, San Francisco, San Francisco, CA
Pamela N. Munster , Manuela Terranova Barberio , Nela Pawlowska , Mark Moasser , Amy Jo Chien , Michelle E. Melisko , Hope S. Rugo , Kamran Abri , Armand Harb , Travis Deal , Adil Daud , Scott Thomas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT02395627
Citation
J Clin Oncol 36, 2018 (suppl; abstr 1044)
DOI
10.1200/JCO.2018.36.15_suppl.1044
Abstract #
1044
Poster Bd #
125
Abstract Disclosures
Similar Posters
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Role for immune checkpoint blockade in BRCA2-mutant prostate cancer.
First Author: Anshuman Panda
Poster
2024 ASCO Genitourinary Cancers Symposium
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
First Author: Michelle Hsu
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 1 trial of combined MEK, STAT3 and PD-1 inhibition in metastatic pancreatic ductal adenocarcinoma (PDAC).
First Author: Peter Joel Hosein
Poster
2023 ASCO Genitourinary Cancers Symposium
Digital evaluation of tumor microenvironment immune markers pre- and post-neoadjuvant pembrolizumab in muscle-invasive bladder cancer (Pure-01 trial: An open label, single arm, phase II study).
First Author: Laura Cattaneo